These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22818151)

  • 1. [Localised prostate cancer: the PREFERE trial].
    Stöckle M; Bussar-Maatz R
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(5):333-5; discussion 335. PubMed ID: 22818151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The importance of pathology in the German prostate cancer study PREFERE].
    Kristiansen G; Stöckle M; Albers P; Schmidberger H; Martus P; Wellek S; Härter M; Bussar-Maatz R; Wiegel T
    Pathologe; 2013 Sep; 34(5):449-62. PubMed ID: 23963533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
    Wiegel T; Albers P; Bartkowiak D; Bussar-Maatz R; Härter M; Kristiansen G; Martus P; Wellek S; Schmidberger H; Grozinger K; Renner P; Schneider F; Burmester M; Stöckle M
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):235-242. PubMed ID: 32886212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer].
    Schmedders M; Janatzek S; Zimmer B
    Urologe A; 2011 Aug; 50(8):938-43. PubMed ID: 21720836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of patient education materials for the "German Prostate Cancer Trial PREFERE"].
    Sänger S; Wiegel T; Stöckle M; Härter M; Bergelt C
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(1):28-39. PubMed ID: 25839363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013].
    Wiegel T; Albers P; Bussar-Maatz R; Gottberg A; Härter M; Kieser M; Kristiansen G; Nettekoven G; Martus P; Schmidberger H; Wellek S; Stöckle M
    Urologe A; 2013 Apr; 52(4):576-9. PubMed ID: 23571802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer.
    Peschel RE; Colberg JW
    Lancet Oncol; 2003 Apr; 4(4):233-41. PubMed ID: 12681267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of early prostate cancer.
    Horwich A; Parker CC; Huddart RA; Dearnaley DP
    Ann Oncol; 2002; 13 Suppl 4():83-7. PubMed ID: 12401671
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
    Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
    BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of four treatment options for low-risk prostate cancer: Preference-based randomized study for the evaluation of four treatment modalities in prostate cancer with low or "early intermediate" risk (PREFERE) - trial AP 65/11 of the AUO].
    Rexer H; Bussar-Maatz R
    Urologe A; 2015 May; 54(5):723-5. PubMed ID: 25802104
    [No Abstract]   [Full Text] [Related]  

  • 16. A systematic overview of radiation therapy effects in prostate cancer.
    Nilsson S; Norlén BJ; Widmark A
    Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PREFERE - Study on the rise].
    Ohlmann CH; Stöckle M; Albers P; Schmidberger H; Härter M; Kristiansen G; Martus P; Wellek S; Bussar-Maatz R; Wiegel T
    Urologe A; 2016 Mar; 55(3):313-7. PubMed ID: 26908120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.
    Gomez-Veiga F; Mariño A; Alvarez L; Rodriguez I; Fernandez C; Pertega S; Candal A
    BJU Int; 2012 Feb; 109 Suppl 1():17-21. PubMed ID: 22239225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low dose brachytherapy with seeds--an interdisciplinary therapy alternative to radical prostatectomy].
    Kahmann F; Henkel T
    Praxis (Bern 1994); 2001 Sep; 90(36):1523-31. PubMed ID: 11593908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.